Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAFV600 Mutation”

31 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 31 results

Testing effectiveness (Phase 2)Study completedNCT02537600
What this trial is testing

Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis

Who this might be right for
Malignant Melanoma
Center Eugene Marquis 43
Testing effectiveness (Phase 2)Study completedNCT02278133
What this trial is testing

Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations

Who this might be right for
Metastatic Colorectal Cancer
Array BioPharma 20
Testing effectiveness (Phase 2)UnknownNCT03514901
What this trial is testing

To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.

Who this might be right for
Melanoma MetastaticBRAF V600 Mutation
Intergruppo Melanoma Italiano 120
Early research (Phase 1)Study completedNCT01656642
What this trial is testing

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Genentech, Inc. 67
Early research (Phase 1)Ended earlyNCT01519323
What this trial is testing

BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 6
Testing effectiveness (Phase 2)Study completedNCT02834364
What this trial is testing

BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)

Who this might be right for
Relapsed or Refractory Multiple MyelomaPatients With BRAFV600 E or BRAFV600K Mutation
University of Heidelberg Medical Center 12
Testing effectiveness (Phase 2)Study completedNCT02583516
What this trial is testing

Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma

Who this might be right for
Melanoma
Grupo Español Multidisciplinar de Melanoma 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT03581292
What this trial is testing

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

Who this might be right for
Anaplastic AstrocytomaGlioblastomaMalignant Glioma
National Cancer Institute (NCI) 38
Large-scale testing (Phase 3)Study completedNCT02908672
What this trial is testing

Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Who this might be right for
Melanoma
Hoffmann-La Roche 514
Testing effectiveness (Phase 2)WithdrawnNCT05299580
What this trial is testing

"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

Who this might be right for
Melanoma
Fondazione Melanoma Onlus
Early research (Phase 1)Study completedNCT01844674
What this trial is testing

A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies

Who this might be right for
Malignant Melanoma, Neoplasms
Hoffmann-La Roche 18
Early research (Phase 1)Study completedNCT01765569
What this trial is testing

A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma

Who this might be right for
Malignant Melanoma, Neoplasms
Hoffmann-La Roche 29
Early research (Phase 1)WithdrawnNCT01843738
What this trial is testing

Radiation Use During Vemurafenib Treatment

Who this might be right for
BRAFV600 MutationStage IV Melanoma
University of Utah
Testing effectiveness (Phase 2)WithdrawnNCT02263898
What this trial is testing

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

Who this might be right for
Recurrent MelanomaStage IV Melanoma
Jonsson Comprehensive Cancer Center
Post-approval studies (Phase 4)Ended earlyNCT01683188
What this trial is testing

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Who this might be right for
Metastatic Melanoma
Clinigen, Inc. 53
Early research (Phase 1)Study completedNCT01851824
What this trial is testing

The Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Who this might be right for
Malignant Melanoma, Neoplasms
Hoffmann-La Roche 9
Post-approval studies (Phase 4)WithdrawnNCT07092410
What this trial is testing

Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib

Who this might be right for
Melanoma BRAF V600E/K Mutated
SRH Wald-Klinikum Gera GmbH
Testing effectiveness (Phase 2)Ended earlyNCT01981187
What this trial is testing

LGX818 for Patients With BRAFV600 Mutated Tumors

Who this might be right for
Solid TumorHematologic Malignancies
Pfizer 12
Testing effectiveness (Phase 2)Study completedNCT01894672
What this trial is testing

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Who this might be right for
Melanoma
Memorial Sloan Kettering Cancer Center 7
Not applicableLooking for participantsNCT04045691
What this trial is testing

Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment

Who this might be right for
Melanoma Stage IVMelanoma Stage III
Pierre Fabre Pharma GmbH 750
Next Page